Last Price
5.02
Today's Change
-0.10 (1.95%)
Day's Change
4.92 - 5.26
Trading Volume
266,981
Market Cap
163 Million
Shares Outstanding
32 Million
Avg Volume
406,058
Avg Price (50 Days)
4.35
Avg Price (200 Days)
4.87
PE Ratio
-5.65
EPS
-0.89
Earnings Announcement
12-Nov-2024
Previous Close
5.12
Open
5.25
Day's Range
4.92 - 5.26
Year Range
2.68 - 7.28
Trading Volume
268,660
1 Day Change
-1.76%
5 Day Change
18.91%
1 Month Change
23.89%
3 Month Change
5.67%
6 Month Change
-25.92%
Ytd Change
-1.76%
1 Year Change
-15.03%
3 Year Change
7.25%
5 Year Change
76.49%
10 Year Change
-88.02%
Max Change
-98.88%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.